Carl Zeiss Meditec appoints Andrew Ihan Chang to lead Global Sales for Ophthalmic Devices

The Medical Technology Business Group of ZEISS has appointed Andrew Ihan Chang to lead its worldwide sales organization for the newly consolidated Strategic Business Unit Global Ophthalmic Devices.

DUBLIN, CA USA / JENA, GERMANY, September 9, 2016.

In August 2016, Carl Zeiss Meditec consolidated its ophthalmic diagnostic and surgical business into a single Strategic Business Unit (SBU) Global Ophthalmic Devices headed by Jim Mazzo. ZEISS announces that the Global Sales organization for the newly consolidated SBU, comprised of Surgical Ophthalmology, Ophthalmic Diagnostics and Refractive Lasers, will be led by Andrew Ihan Chang.

“Andy Chang’s appointment is the next crucial step in strengthening ZEISS’ commitment to our customers,” says Jim Mazzo, Global President Ophthalmic Devices of Carl Zeiss Meditec. “Andy joins ZEISS at a pivotal time with the consolidation of our ophthalmic business worldwide. His appointment underscores our mission to collaborate more closely with doctors to provide unique innovations and technology solutions to increase efficiency in their daily practice and deliver the best patient care.”

“Andy has a breathe of experience across the ophthalmic industry in diagnostic and surgical devices, as well as pharmaceuticals. He has exceptional understanding of what ophthalmologists and optometrists need to achieve and the challenges they face in daily practice,” Jim Mazzo continues. “He has a proven track record of partnering with doctors from early stage development through integration and implementation of cutting-edge technologies into daily clinical practice, addressing the need for clinical performance and efficiency from diagnosis through surgery. Andy’s customer-focused leadership and philosophy of partnership, collaboration and cross-over integration with clinicians supports expanding our offerings to our ophthalmic and optometric customers worldwide. His understanding of the needs of the clinician and how technology can improve their work has successfully transitioned some of the ophthalmic industry’s most influential companies to the next level in market leadership.”

“I am honored to join ZEISS, a world-class organization, a global leader in innovation and technology, and to work with Jim Mazzo, one of the most respected leaders in the ophthalmic industry. I am excited to lead its global sales organization during this exciting new chapter for the company, and to be part of strengthening ZEISS’ partnership with customers in the development and implementation of new products and applications. I am looking forward to meeting our customers around the world and to understand how ZEISS can help them achieve success in their daily practice.” says Mr. Chang.

Prior to joining ZEISS, Chang was General Manager and Senior Vice President for Bausch + Lomb Surgical where he led the sales, marketing, operations and business development for the US. Previously at Optimedica Corporation / Abbott Medical Optics, Inc., Chang led the marketing and launch of new laser systems and new indications globally. At ISTA Pharmaceutical / Bausch + Lomb, Chang held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals.

Contacts for the press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: + 49 3641 220-331
Email: press .meditec @zeiss .com

Alice Genevieve Swinton
Director Communications, Carl Zeiss Meditec, Inc.
Phone: +1 925 560 5163
Email: alice .swinton @zeiss .com

For investors

Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49 3641 220-116
Email: investors .meditec @zeiss .com

www.meditec.zeiss.com/press

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of ZEISS is rounded off by promising future technologies such as intraoperative radiation therapy. With approximately 2,900 employees worldwide, the Group generated revenue of € 1,040 million in financial year 2014/2015 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries.

For more information visit our website at: www.zeiss.com/med

We use cookies on this site. Cookies are small text files that are stored on your computer by websites. Cookies are widely used and help to optimize the pages that you view. By using this site, you agree to their use. more